TNFSF13B and metabolic dysfunction-associated steatotic liver disease: HFD-fed BAFF-Tg (Fig. 1i–m; Supplementary Fig. 4) and μMT (Supplementary Fig. 5) mice were protected from weight-driven glucose dysmetabolism (e.g., fasting glucose and GTT) and NAFLD progression (hepatic triglyceride levels and alanine transaminase [ALT]).